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Abstract
Background: Post-herpetic neuralgia (PHN) is a common type of neuropathic pain that can severely affect quality
of life. NGX-4010, a capsaicin 8% dermal patch, is a localized treatment that can provide patients with significant
pain relief for up to 3 months following a single 60-minute application. The NGX-4010 application can be
associated with application-site pain and in previous clinical trials pretreatment with a topical 4% lidocaine
anesthetic was used to enhance tolerability. The aim of the current investigation was to evaluate tolerability of
NGX-4010 after pretreatment with lidocaine 2.5%/prilocaine 2.5% anesthetic cream.
Methods: Twenty-four patients with PHN were pretreated with lidocaine 2.5%/prilocaine 2.5% cream for 60
minutes before receiving a single 60-minute application of NGX-4010. Tolerability was assessed by measuring patch
application duration, the proportion of patients completing over 90% of the intended treatment duration,
application site-related pain using the Numeric Pain Rating Scale (NPRS), and analgesic medication use to relieve
such pain. Safety was assessed by monitoring adverse events (AEs) and dermal irritation using dermal assessment
scores.
Results: The mean treatment duration of NGX-4010 was 60.2 minutes and all patients completed over 90% of the
intended patch application duration. Pain during application was transient. A maximum mean change in NPRS
score of +3.0 was observed at 55 minutes post-patch application; pain scores gradually declined to near pre-
anesthetic levels (+0.71) within 85 minutes of patch removal. Half of the patients received analgesic medication on
the day of treatment; by Day 7, no patients required medication. The most common AEs were application site-
related pain, erythema, edema, and pruritus. All patients experienced mild dermal irritation 5 minutes after patch
removal, which subsequently decreased; at Day 7, no irritation was evident. The maximum recorded dermal
assessment score was 2.
Conclusion: NGX-4010 was well tolerated following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in
patients with PHN. The tolerability of the patch application appeared comparable with that seen in other studies
that used 4% lidocaine cream as the pretreatment anesthetic. This study is registered at http://www.clinicaltrials.
gov as number NCT00916942.
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Neuropathic pain is pain arising as a direct consequence
of a lesion or disease affecting the somatosensory system
[1]. Post-herpetic neuralgia (PHN) is a common type of
neuropathic pain occurring as a complication of reacti-
vation of the varicella zoster virus (shingles). PHN is
caused by damage to the small-diameter sensory C and
Aδ fibers within primary afferent neurons, which results
in hypersensitivity and exaggerated responses to nor-
mally innocuous stimuli (evoked pain), as well as both
continuous and paroxysmal spontaneous pain [2-6].
Symptoms of PHN include pain from normally non-
noxious stimuli such as the brush of clothing (allodynia),
increased sensitivity to painful stimuli (hyperalgesia),
intermittent stabbing or lancinating pain and constant
deep burning [2,7]. The pain caused by PHN can be
highly debilitating and can severely affect patients’ qual-
ity of life [2,5,6].
Neuropathic pain therapies include adjunctive analge-
sic antidepressants and anticonvulsants, as well as
opioids and various topical treatments such as lidocaine
or low-concentration capsaicin [8,9]. These treatment
options commonly provide pain relief in only a subset
of patients with neuropathic pain, and the relief that is
achieved is often only partial [6]. Additionally, systemic
treatments can be accompanied by a significant side
effect burden that can include dizziness, somnolence,
and nausea. There are also a number of contraindica-
tions and potential drug-drug interactions to take into
account with systemic neuropathic pain treatments,
especially in the often elderly population of patients
with PHN [6,9]. Together, these factors highlight the
unmet need in the treatment of PHN.
A recent development for the treatment of patients
with PHN is a capsaicin 8% w/w dermal patch
(QUTENZA™, NGX-4010). Capsaicin is a selective ago-
nist of Transient Receptor Potential Vanilloid 1
(TRPV1) receptors, which are activated by noxious heat,
low pH, and some endogenous inflammatory mediators
[10,11]. TRPV1 receptors are ligand-gated cation chan-
nels and are expressed on the majority of C and Aδ
fibers [10,12]. Exposure of TRPV1 receptors to high
concentrations of capsaicin initially causes depolariza-
tion, action potential initiation, and burning pain. How-
ever, this is followed by a reversible defunctionalization
and reduction of epidermal nerve fibers [12,13] resulting
in a prolonged inhibition of pain transmission. NGX-
4010 has been demonstrated to provide significant pain
relief for up to 3 months to patients with PHN or HIV-
associated neuropathy [12,14-17].
Administration of NGX-4010 is associated with pain,
erythema, and other application-site reactions. In pre-
vious clinical trials, 4% lidocaine cream was used as pre-
treatment and the procedure appeared well tolerated,
with the great majority of patients receiving treatment
for over 90% of the intended treatment duration
[12,14-17]. The objective of the current study was to
evaluate the tolerability of NGX-4010 after pretreatment
with an alternative topical anesthetic, lidocaine 2.5%/pri-
locaine 2.5% anesthetic cream, in patients with PHN,
since 4% lidocaine cream is not available in all of the
countries in which NGX-4010 is approved. Lidocaine
2.5%/prilocaine 2.5% cream is a eutectic mixture of local
anesthetics (EMLA™) and a commonly available topical
anesthetic formulation. The efficacy of lidocaine 2.5%/
prilocaine 2.5% cream has been shown to be comparable
with that of 4% lidocaine alone in a number of proce-
dures, such as prior to chemical peeling, minor surgical
procedures, or laser hair removal [18-20].
Methods
Patients
Patients aged 18-90 years with pain due to PHN that
persisted for at least 3 months after shingles vesicle
crusting and was of appropriate severity for treatment
with NGX-4010 in the opinion of the investigator, were
eligible for study entry. Patients were not permitted to
take part if they were already receiving opioid medica-
tions, unless these were taken orally or transdermally
and the daily dose did not exceed 60 mg/day of mor-
phine or equivalent. Patients were not permitted to use
any topical pain medications on the affected areas
within the 7 days preceding treatment or during the
study. Female patients of childbearing age were required
to have had a negative pregnan c yt e s ta tt h es c r e e n i n g
visit, and be using an effective method of contraception
throughout the study period. The study was conducted
in accordance with the Declaration of Helsinki, was con-
sistent with Good Clinical Practice guidelines, and was
approved by the following institutional review board:
Aspire IRB, LLC, 9320 Fuerte Drive, La Mesa, CA. Writ-
ten informed consent was obtained from all participat-
ing patients before the study commenced.
Procedures
This was a 7-day, open-label, non-controlled, non-ran-
domized, multicenter study with a total of three visits–
Screening, Day 0 (treatment day), and Day 7. All
patients were assigned to receive open-label NGX-4010
(QUTENZA™, NeurogesX Inc., San Mateo, CA, USA),
a capsaicin 8% w/w (640 μg/cm
2) patch. Patients could
receive up to four patches (280 cm
2 each) corresponding
to a total treatment area of 1,120 cm
2. Painful areas
were identified and pretreated with a thick layer of lido-
caine 2.5%/prilocaine 2.5% cream (1-2 g/10 cm
2), then
covered with Tegaderm™ Film (3M Health Care, Neuss,
Germany) for 60 minutes to prevent drying out. After
the anesthetic cream was removed, the skin was washed
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Page 2 of 8with soap and water, and dried. NGX-4010 patches were
cut to size and applied to the pretreated areas for 60
minutes. Patients were permitted to use immediate-
release, opioid-based, oral pain medications such as oxy-
codone hydrochloride oral solution (1 mg/mL concen-
tration) in the clinic as needed for relief of treatment-
related discomfort. Local cooling measures could also be
used following patch removal. Patients were permitted
to take hydrocodone bitartrate/acetaminophen (5/500
mg) as needed for up to 5 days following treatment.
Assessments
This was primarily a safety study so there were no
assessments for the efficacy of NGX-4010. Safety and
tolerability analyses were performed on all enrolled
patients who received study drug.
To determine the tolerability of NGX-4010 following
pretreatment with the lidocaine 2.5%/prilocaine 2.5%
anesthetic cream, the following were assessed: mean
duration of patch application; mean changes in “Pain
Now” NPRS scores from pretreatment values on the day
of treatment; the proportion of patients using analgesic
medication for treatment-associated pain during and fol-
lowing patch application on the day of treatment and on
Days 0 to 7 and the mean daily dose; and the proportion
of patients completing at least 90% of the intended patch
application duration. The sample size for this study was
based on clinical judgment to adequately assess the toler-
ability of NGX-4010 in conjunction with a topical anes-
thetic formulation for the treatment of PHN.
Adverse events (AEs) were monitored throughout the
study from application of the topical anesthetic to study
end. AEs were mapped to preferred term and system
organ class using the Medical Dictionary for Drug Regula-
tory Activities (MedDRA, version 10.1). Vital signs, includ-
ing blood pressure and heart and respiratory rates, were
monitored at all study visits. On the treatment day, vital
signs and NPRS “Pain Now” scores were recorded imme-
diately prior to anesthetic application, 30 and 55 minutes
after anesthetic application, 25 and 55 minutes after patch
application, and 5, 25, 55, and 85 minutes after patch
removal. In addition, “Pain Now” NPRS scores were
recorded on the evening of the treatment day.
Dermal assessments were carried out at all study visits
and on the treatment day, before anesthetic application,
within 5 minutes of its removal, and following patch
removal within 5 minutes and at 25, 55, and 85 minutes,
using the following scoring system [21]: 0 = no evidence
of irritation, 1 = minimal erythema, barely perceptible, 2
= definite erythema, readily visible; minimal edema or
minimal papular response, 3 = erythema and papules, 4
= definite edema, 5 = erythema, edema, and papules, 6
= vesicular eruption, 7 = strong reaction spreading
beyond test site.
Results
Patient disposition
A total of 25 subjects were enrolled in the study and 24
received study drug treatment. One patient did not
receive treatment with NGX-4010 due to an increase in
blood pressure that occurred during treatment with the
topical anesthetic. Three patients (12%), including the
patient who did not receive NGX-4010 treatment, with-
drew from the study prematurely; the other two with-
drawals were due to scheduling conflicts.
Patient demographics
The average age of patients enrolled in the study was
approximately 67 years (Table 1). The mean duration of
PHN pain was 5.5 years and the mean baseline NPRS
score was 5.5. One-third of the patients (eight in total)
had previously received NGX-4010 treatment.
Safety and tolerability
Treatment
The intended duration of treatment was 60 minutes;
the observed mean duration of NGX-4010 patch appli-
cation was 60.2 minutes (Table 2). Four patients
received NGX-4010 treatment for longer than 60 min-
utes and 1 patient had the patch removed after 59
minutes. All 24 patients completed at least 90% of the
intended patch application duration. The mean appli-
cation duration of the topical anesthetic was 60.9 min-
utes and the mean surface area treated with NGX-
4010 was 407 cm
2.
Table 1 Patient Demographics
NGX-4010 (n = 24)
Age (years)
Mean (SD) 66.9 (11.8)
Min, max 39, 83
Gender, n (%)
Male 13 (54)
Race, n (%)
White 23 (96)
African American 1 (4)
Other 0
Duration of PHN pain (years)
Mean (SD) 5.5 (4.3)
Min, max 1.0, 19.3
Pain level at screening
Mean (SD) 4.3 (2.2)
Min, max 0, 9.0
Baseline pain level
Mean (SD) 5.5 (1.7)
Min, max 2.1, 8.9
Abbreviations: PHN; post-herpetic neuralgia, SD; standard deviation.
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The mean absolute NPRS score was 4.7 before treatment,
decreased following anesthetic application and then
increased following application of NGX-4010 (Figure 1).
A maximum mean increase in NPRS score of 3.0 was
recorded just before removal of NGX-4010. The score
quickly declined following patch removal to less than half
the maximum within 5 minutes of patch removal (+1.4)
and returned to near pre-anesthetic levels (+0.7) within
85 minutes of patch removal (Figure 1). Four patients
(17%) had no increase in pain from the pretreatment
level during patch application or after removal. On the
evening of the treatment day, mean NPRS scores
remained at near pretreatment levels (Figure 1).
Half of the patients treated with NGX-4010 received
medication on the day of application (study Day 0) for
treatment-related discomfort. A total of 10 patients (42%)
received immediate-release, opioid-based analgesic medi-
cation (oxycodone or oxycodone-based medication), 3
patients (13%) received hydrocodone (or hydrocodone-
based medication), and 1 patient (4%) received acetamino-
phen. The mean dose of opioid medication received on
Day 0 was 11.5 mg for oxycodone and 15.0 mg for hydro-
codone. The number of patients receiving medication for
treatment-related discomfort decreased rapidly after the
day of NGX-4010 treatment, with only 4 patients receiving
medication on Day 1, 2 patients on Day 3, 1 patient on
Days 5 and 6 and no patients on Day 7.
Adverse Events
All 24 patients within the study reported at least one
treatment-emergent AE (Table 3). The most common
treatment-emergent AEs were application-site related,
with 100% of patients reporting application-site
erythema, 92% reporting application-site pain, 17%
reporting application-site edema, and 4% reporting
application-site pruritus (Table 3). There was one case
of increased blood pressure considered to be treatment
related; however, this was mild and resolved on the day
of treatment. The majority of patients reported treat-
ment-emergent AEs that were mild to moderate in
severity. Application-site pain was the only severe treat-
ment-emergent AE and was reported by 3 patients
(13%; Table 3). All application-site AEs were resolved by
Day 7.
No serious AEs or deaths occurred during the study
period. A transient increase in mean blood pressure was
observed during the application procedure (Figure 2).
Blood pressure levels increased following administration
of the NGX-4010 patch and reached the maximum
mean increase in systolic blood pressure of 11.8 mm
Hg, 55 minutes after application. Following patch
Table 2 Extent of Exposure to Lidocaine 2.5%/Prilocaine
2.5% and NGX-4010
NGX-4010
(n = 24)
Duration of topical anesthetic application (minutes)
Mean (SD) 60.9 (3.0)
Min, max 56, 72
Duration of NGX-4010 patch application (minutes)
Mean (SD) 60.2 (0.7)
Min, max 59, 63
Surface area treated (cm
2)
Mean (SD) 407 (301)
Min, max 59, 1000
Number of subjects completing at least 90% of intended
NGX-4010 patch application time, n (%)
24 (100)
Abbreviations: SD; standard deviation.
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Page 4 of 8removal, blood pressure levels gradually decreased
toward the pretreatment level. At 85 minutes post-patch
removal, the mean increase from pretreatment was 5.2
mm Hg. No changes in heart or respiratory rates were
observed on the day of treatment.
Dermal Assessments
Prior to application of the topical anesthetic, all patients
had a dermal assessment score of 0, i.e. there was no
evidence of erythema or dermal irritation (Figure 3).
Following removal of the anesthetic cream, 2 patients
had mild dermal irritation; 1 patient had a score of 1
(minimal erythema); and 1 patient had a score of 2
(definite erythema, minimal edema, or minimal papular
response). Although all patients showed some dermal
irritation after patch removal, no patients reached a
score > 2. After patch removal, dermal irritation
declined and there was no evidence of irritation in any
patients on Day 7.
Table 3 Treatment-emergent Adverse Events by System Organ Class and Preferred Term
System organ class Preferred term, n (%) NGX-4010 (n = 24) Mild Moderate Severe
Number of subjects reporting one or more treatment-emergent AEs 24 (100.0) 6 (25.0) 14 (58.3) 4 (16.7)
General disorders and administration-site conditions 24 (100.0) 6 (25.0) 15 (62.5) 3 (12.5)
Application-site erythema* 24 (100.0) 9 (37.5) 15 (62.5) 0 (0)
Application-site pain* 22 (91.7) 4 (16.7) 15 (62.5) 3 (12.5)
Application-site edema* 4 (16.7) 3 (12.5) 1 (4.2) 0 (0)
Application-site pruritus* 1 (4.2) 1 (4.2) 0 (0) 0 (0)
Pain 1 (4.2) 0 (0) 0 (0) 1 (4.2)
Investigations 1 (4.2) 1 (4.2) 0 (0) 0 (0)
Blood pressure increased* 1 (4.2) 1 (4.2) 0 (0) 0 (0)
Musculoskeletal and connective tissue disorders 2 (8.3) 1 (4.2) 0 (0) 1 (4.2)
Back pain 2 (8.3) 1 (4.2) 0 (0) 1 (4.2)
Muscular weakness 1 (4.2) 1 (4.2) 0 (0) 0 (0)
Reproductive system and breast disorders 1 (4.2) 0 (0) 1 (4.2) 0 (0)
Breast mass 1 (4.2) 0 (0) 1 (4.2) 0 (0)
Skin and subcutaneous tissue disorders 3 (12.5) 3 (12.5) 0 (0) 0 (0)
Erythema 1 (4.2) 1 (4.2) 0 (0) 0 (0)
Rash papular 2 (8.3) 2 (8.3) 0 (0) 0 (0)
Note: counts indicate the numbers of subjects reporting one or more AEs that mapped to the MedDRA (version 10.1) system organ class. At each level of
summarization, subjects were only counted once, according to the greatest severity. Abbreviations: AE; adverse event.
*AEs categorized as possibly or probably related to treatment.
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Figure 2 Change in systolic blood pressure on the treatment day. Blood pressure was recorded on the day of treatment before and during
application of lidocaine 2.5%/prilocaine 2.5% cream, during NGX-4010 administration, and up to 85 minutes following patch removal. The results
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Based on assessment of the duration of NGX-4010
patch application, the pain experienced during treatment
and the number of patients requiring analgesic medica-
tion to relieve treatment-related pain, the results of this
study suggest that lidocaine 2.5%/prilocaine 2.5% cream
is an acceptable pretreatment for 60-minute NGX-4010
applications. The mean duration of NGX-4010 applica-
tion was 60.2 minutes and all patients received treat-
ment for more than 90% of the intended treatment
duration. This is comparable with previous trials in
which patients were pretreated with 4% lidocaine cream
where nearly all patients received treatment for 90% or
more of the intended treatment duration [14,15,17].
In the present study, the pain experienced during and
following NGX-4010 treatment was transient, with
mean NPRS scores returning to pre-anesthetic levels
(+0.7, 95% CI: -0.68, 2.09) within 85 minutes of patch
removal. This result is similar to that of a previous
report also showing a transient increase in pain during
NGX-4010 application, and a return of mean NPRS
scores to pre-anesthetic levels (+0.4) by 85 minutes
post-patch removal [17]. The maximum mean increase
in NPRS score of 3.0 (95% CI: 1.79, 4.21) observed just
before removal of NGX-4010 in the present study was
comparable with the mean NPRS score increases of 2.0
to 2.8 observed in a long-term safety study that included
PHN patients [22]. Half of the patients used analgesic
medication on the day of treatment for application site-
related pain; this number rapidly decreased on subse-
quent days, with only 4 patients requiring medication
on Day 1 and no patients requiring pain medication by
Day 7. Nearly half of the patients (54%) used medication
for treatment-related discomfort on Days 0-5. Again
t h e s er e s u l t sa r es i m i l a rt ot h o s ep r e v i o u s l yo b s e r v e di n
studies employing 4% lidocaine as pretreatment in
patients with PHN, during which between 48 and 62%
of patients used medication for treatment-related dis-
comfort on Days 0-5 [14,15,17]. The level of dermal irri-
tation that occurred during and after NGX-4010
application was also comparable with that which was
observed in previous studies when 4% lidocaine was
used as a pretreatment, where the majority of patients
reported a maximum score of 2 or less [15,17].
The most common treatment-emergent AEs were appli-
cation site-related pain and erythema. The incidence of
application-site erythema in this study (100%) was similar
to an incidence of 94% and 92% reported in previous stu-
dies of NGX-4010 in patients with PHN [14,17]. Applica-
tion-site pain was reported by 92% of patients in the
current investigation and was slightly higher than an inci-
dence of 56% and 63% of patients reported in two previous
studies [14,17]. However, despite this higher incidence of
application-site pain, the pain increase and the use of
medication for treatment-related discomfort was compar-
able, as described above. There was also a comparable
effect on blood pressure during NGX-4010 application
between patients pretreated with lidocaine 2.5%/prilocaine
2.5% cream and those in previous clinical trials pretreated
with 4% lidocaine. Changes in blood pressure were asso-
ciated with treatment-related changes in pain; in previous
studies blood pressure increases were on average < 10 mm
Hg [23], while in the current study the maximum mean
increase was 11.8 mm Hg (95% CI: 5.3, 18.3).
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Figure 3 Dermal irritation. Dermal assessments were carried out to assess dermal irritation on the day of treatment before and immediately
after application of lidocaine 2.5%/prilocaine 2.5% cream, at various time points following patch removal up to 85 minutes, and on study Day 7.
Results show the percentage of patients at each time point with a dermal assessment score of 0 (no evidence of irritation), 1 (minimal erythema,
barely perceptible), or 2 (definite erythema, readily visible; minimal edema, or minimal papular response), which was the maximum score
recorded. Due to rounding, some figures do not add up to 100. TA; topical anesthetic.
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open-label, non-randomized trial that did not include a
control arm or a comparator arm for the tolerability of
NGX-4010 treatment following pretreatment with lido-
caine 2.5%/prilocaine 2.5% cream. Therefore, direct
comparisons between the tolerability of NGX-4010
treatment following pretreatment with lidocaine 2.5%/
prilocaine 2.5% cream or 4% lidocaine cream cannot be
drawn. This means that it is not possible to confirm
whether NGX-4010 treatment is equally tolerable fol-
lowing pretreatment with either topical anesthetic
cream. As there was no control arm, it is also not possi-
ble to compare directly the tolerability of NGX-4010
after lidocaine 2.5%/prilocaine 2.5% cream pretreatment
with the tolerability after no anesthetic cream pretreat-
ment. Consequently, it is not possible to determine
whether pretreatment with lidocaine 2.5%/prilocaine
2.5% cream is essential for the tolerability of NGX-4010
treatment. However, the objective of this study was to
investigate the tolerability of NGX-4010 treatment fol-
lowing pretreatment with lidocaine 2.5%/prilocaine 2.5%
cream, because 4% lidocaine cream is not available in all
of the countries in which NGX-4010 is approved.
Despite the limitations of an open-label, non-rando-
mized study, these objectives were met, with the data
showing that NGX-4010 is a tolerable treatment follow-
ing pretreatment with lidocaine 2.5%/prilocaine 2.5%
cream. Other limitations of this study included the
small sample size and lack of long-term follow-up. How-
ever, all application-site AEs in this study were short
term and transient, resolving within 7 days and longer
follow-up would not have provided additional tolerabil-
ity information.
Based on the mode of action of lidocaine and prilo-
caine, it is not surprising to find that the tolerability of
NGX-4010 following pretreatment with lidocaine 2.5%/
prilocaine 2.5% appears to be similar to that seen when
4% lidocaine is used as a pretreatment. Both molecules
are amide-type anesthetic agents, with similar chemical
structures [24]. Both act on neuronal membranes by
inhibiting sodium ion channels and consequently the
ionic fluxes that are required for initiation and conduc-
tion of nerve impulses. Through inhibition of sodium
ion influx, the threshold for nerve excitation is increased
until the ability to generate an action potential is lost.
Therefore, both lidocaine and prilocaine stabilize neuro-
nal membranes of dermal pain receptors and nerve end-
ings, resulting in the reduction of pain responses
[24,25]. Previously, lidocaine 2.5%/prilocaine 2.5% cream
has been shown to significantly reduce the burning pain
of low-dose (0.075%) topically applied capsaicin [26],
while axonal blockade with lidocaine can prevent the
pain and hyperalgesia of intradermal capsaicin [27].
Conclusions
In summary, NGX-4010 is a treatment option for PHN
that may provide significant pain relief for up to 3
months from a single 60-minute application. Adminis-
tration of the capsaicin 8% patch may be associated with
application site-related pain that can be managed by
pretreatment of the painful area with a topical anes-
thetic and the use of local cooling and short-acting oral
analgesics. Previous clinical trials utilized 4% lidocaine
cream as pretreatment; however, other topical anes-
thetics may also be used. Results from the current inves-
tigation provide evidence that NGX-4010 is tolerable
following pretreatment with lidocaine 2.5%/prilocaine
2.5% cream. Moreover, tolerability appears comparable
with the tolerability observed in the clinical trials using
4% lidocaine cream as pretreatment, in terms of
intended application duration, extent of application site-
related pain, use of medication for treatment-related dis-
comfort, dermal irritation, AE profile, and transient
blood pressure changes. Therefore, this study demon-
strates that lidocaine 2.5%/prilocaine 2.5% cream is an
acceptable alternative topical anesthetic for pretreatment
prior to NGX-4010 application.
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